Supplementary Table from Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer

Thomas, Parijatham S.; Patel, Anisha B.; Lee, J. Jack; Liu, Diane D.; Hernandez, Mike; Muzzio, Miguel; Contreras, Alejandro; Sepeda, Valerie; Mays, Carrie; Weber, Diane; Vornik, Lana A.; Khan, Seema A.; Dimond, Eileen; Heckman-Stoddard, Brandy M.; Perloff, Marjorie; Brown, Powel H.

doi:10.1158/1940-6207.22533313.v1

Supplementary Table from Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer

https://doi.org/10.1158/1940-6207.22533313

journal contribution

posted on 2023-04-03, 22:01 authored by Parijatham S. Thomas, Anisha B. Patel, J. Jack Lee, Diane D. Liu, Mike Hernandez, Miguel Muzzio, Alejandro Contreras, Valerie Sepeda, Carrie Mays, Diane Weber, Lana A. Vornik, Seema A. Khan, Eileen Dimond, Brandy M. Heckman-Stoddard, Marjorie Perloff, Powel H. Brown

Supplementary Table from Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer

Funding

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

Duncan Family Institute for Cancer Prevention and Risk Assessment (Duncan Family Institute)

History

Related Materials

1.
DOI - Is supplement to Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer

ARTICLE ABSTRACT

Bexarotene is a rexinoid that has been shown to prevent mammary tumors in mouse models but oral dosing has toxicities. This phase I study evaluates topical bexarotene, as a potential chemoprevention agent, for safety and toxicity in high-risk women for breast cancer.

Supplementary Table from Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer

Funding

National Cancer Institute (NCI)

Duncan Family Institute for Cancer Prevention and Risk Assessment (Duncan Family Institute)

History

Related Materials

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports